Allogeneic Anti-BCMA CAR T Cells Are Superior to Multiple Myeloma-derived CAR T Cells in Preclinical Studies and May Be Combined with Gamma Secretase Inhibitors

Ana M. Metelo(London Cancer), Reuben Benjamin(King's College London), Cesar Sommer(Allogene Therapeutics (United States)), Barbra J. Sasu(Unknown), Kirsty Cuthill, Katy Sanchez(King's College Hospital), Charlotte Attwood(London Cancer), Agnieszka Jóźwik(King's College Hospital NHS Foundation Trust), Matthew Streetly(King's College - North Carolina), Alan Dunlop(King's College Hospital), Le Anh Luong(University of Minnesota), Trevor Bentley(Allogene Therapeutics (United States)), Charlotte Graham(Broad Institute), Delaney Dominey-Foy(London Cancer), Carmel Rice(King's College Hospital NHS Foundation Trust), Shafqat Inam(The Alfred Hospital), Bijan Boldajipour(University of Münster)
Cancer Research Communications
March 23, 2022
Cited by 39


Related Papers